(January 12, 2017, 10:55 AM EST) -- WASHINGTON, D.C. — An appellant seeking to challenge a final written decision by the Patent Trial and Appeal Board that confirmed the validity of a conjugated antibody patent was turned away on Jan. 9 by the Federal Circuit U.S. Court of Appeals (Phigenix Inc. v. ImmunoGen Inc., No. 16-1544, Fed. Cir.; 2017 U.S. App. LEXIS 323)....